Valuation
- Market cap
- 1,827,324,000
- Revenue TTM
- $1,258,400,000
- Net income TTM
- $363,050,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 28.85%
- Debt to equity
- 0.00
Trading
- Volume
- 288,000
- Avg volume
- 166,174
- Day's range
- $27.15 – $28.53
- Shares out
- 65,897,000
- Stochastic %K
- 32%
- Beta
- 0.25
- Analysts
- Moderate Sell
- Price target
- $30.17
Company profile
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; a...
Show more
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 32 1 534 29 00
- Website
- https://www.glpg.com
- Address
- Generaal De Wittelaan L11 A3, Mechelen, Belgium
Latest news
No headlines yet.
